Bone marrow cells expressing the surface antigen CD34 comprise approximately 1% of harvested marrow and are highly enriched for marrow progenitor cells, including the cells believed to be responsible for long-term engraftment following bone marrow transplantation (BMT). Selection of CD34-expressing cells was applied in allogeneic BMT (alloBMT) to decrease the number of T lymphocytes in the infused marrow in an attempt to prevent severe graft-versus-host disease (GVHD). We report 14 patients who underwent HLA-identical sibling-matched alloBMT with marrow-enriched for CD34 cells using the Isolex 300 SA device. Patients received total body irradiation, thiotepa, cyclophosphamide, antithymocyte globulin and methylprednisolone prior to marrow infusion. No post-transplantation immunosuppressive therapy was given except for a 5-week course of steroids. The purity of the infused marrow was 64.9 ؎ 6.0% (mean ؎ s.e.m.) CD34-positive cells and patients received a mean of 1.24 ؎ 0.21 ؋ 10 6 CD34 cells/kg. A mean of 9.4 ؎ 1.7 ؋ 10 4 CD3 T cells/kg were present in the CD34-enriched product, representing a 2.7 ؎ 0.1 log depletion. There were no graft rejections and patients achieved a sustained absolute granulocyte count of Ͼ500 in a median of 10.5 days and a sustained platelet engraftment of Ͼ20 000 untransfused in a median of 27 days. Patients were discharged a median of 21.5 days after marrow infusion. There were no instances of grade III or IV graft-versus-host disease (GVHD) and no unexpected adverse events during the transplant hospitalization. With a median follow-up of 12 months, the estimated 100 day survival is 86 ؎ 9%. CD34 selection in alloBMT permits rapid engraftment without unanticipated toxicities. Keywords: CD34 selection; engraftment; allogeneic transplantation
of which possess a limited life span. Engraftment is believed to arise from a population of cells expressing the surface antigen CD34 which possesses high proliferative capacity and multilineage potential. 1, 2 Since CD34 expression is restricted to a small fraction of hematopoietic cells (representing approximately 1% of harvested marrow), 3 enrichment of CD34 expressing cells may permit removal of contaminating cells from infused marrow. This approach is currently being evaluated in the setting of autologous transplantation for disorders in which marrow is contaminated with neoplastic cells that lack CD34 expression. [4] [5] [6] We, and others, have noted that positive selection of CD34 cells is effective in depleting marrow of T cells. 6, 7 Negative selection of T cells from marrow grafts has been shown to decrease the incidence of graft-versus-host disease (GVHD), with methods providing more than 1.6 log depletion virtually eliminating significant GVHD in siblingmatched BMT. 8, 9 Our preliminary work in autologous BMT indicates that positive selection of CD34 cells by immunomagnetic bead separation using the Isolex 300 SA device results in a greater than 2 log depletion of marrow T cells. 6 In this report, we describe a pilot study to determine the feasibility of utilizing CD34-selected sibling donor marrow in allogeneic bone marrow transplantation (alloBMT). The quality of the infused marrow product, engraftment characteristics, incidence of GVHD, and toxicity of the procedure are reported for 14 patients.
Materials and methods

Treatment protocol
In a study approved by the Indiana University Institutional Review Board and the US Food and Drug Administration, 14 individuals with hematologic malignancies underwent alloBMT using CD34-enriched marrow using the ISOLEX 300 SA device (Baxter Healthcare, Santa Ana, CA, USA). Eligibility criteria included patients less than 56 years of age with a serological 6/6 matched sibling donor. Exclusion criteria included HIV positivity, increased marrow fibrosis (grade 3-4 out of 4), acute leukemia in relapse, chronic myeloid leukemia (CML) in blast crisis or accelerated phase, and CML patients less than 35 years of age. Patients were also ineligible if Ͻ2 ϫ 10 8 nucleated cells/kg were obtained from the donor at marrow harvest. The preparative regimen consisted of hyperfractionated total body irradiation (TBI) with 11 fractions of 125 cGy (total 1375 cGy) given at a dose-rate of 5-20 cGy per min administered on day Ϫ10 to day Ϫ7 at 4-6-h intervals. Lung fields were shielded to reduce the total lung dose to approximately 900 cGy. Splenic irradiation was given to patients with myelodysplastic syndromes (100 cGy per day for 4 consecutive days). Testis irradiation was given to men with the diagnosis of ALL (400 cGy in a single fraction). Following TBI, patients received thiotepa (5 mg/kg/day, days Ϫ5 and Ϫ4), and cyclophosphamide (60 mg/kg/day, days Ϫ3 and Ϫ2). Rejection prophylaxis consisted of methylprednisolone 2 mg/kg/day and antithymocyte globulin (Atgam; Upjohn, Kalamazoo, MI, USA) 30 mg/kg/day on day Ϫ5 to day Ϫ2. Post-transplant rejection prophylaxis consisted of G-CSF (5 mg/kg/day, day ϩ1 until AGC Ͼ2000 for 2 days) and methylprednisolone 2 mg/kg/day beginning day ϩ5 with the dosage halved every 7 days and discontinued on day ϩ41. Patients received prophylactic quinolone antibiotics, fluconazole and weekly immune globulin (500 mg/kg) until day ϩ120. After engraftment, all patients serologically CMV-positive were treated prophylactically with gancyclovir (3 mg/kg every 12 h 5 days a week) until day ϩ120. All blood products were irradiated and leukocyte-depleted.
CD34-positive cell selection
CD34
ϩ cells were isolated from harvested marrow using the Isolex 300 SA Magnetic Cell Separator (Baxter Healthcare, Irvine, CA, USA). Briefly, low density marrow cells were first labeled with a mouse anti-human CD34 monoclonal antibody (9C5; Baxter-Hyland) for 30 min at 4°C. After thorough washing, labeled cells were rosetted with sheep anti-mouse IgG 1 conjugated to paramagnetic microspheres (Baxter-Fenwal) for 30 min after which the formed rosettes were separated from the rest of the cells by a permanent magnet. CD34 ϩ cells contained in the separated rosettes were released from the paramagnetic microspheres by incubating the rosettes with chymopapain (Boots, Nottingham, UK) for 15 min at room temperature. Free microspheres were eliminated by the sequential passing of the cells over two permanent magnets to ensure the removal of all microspheres from the final product. Selected CD34 ϩ cells were washed three times, counted, and analyzed for purity using HPCA-2 (clone 8G12; Becton Dickinson Immunocytometry Systems, San Jose, CA, USA). Cell viability was measured by trypan blue exclusion.
Flow cytometric immunophenotyping
All flow cytometric analysis was performed on a FACScan (Becton Dickinson Immunocytometry Systems, BDIS). List-mode files of 10 4 to 1.5 ϫ 10 4 events were collected for each sample using CellQuest software (BDIS). Cells from all fractions to be analyzed were washed in PBS containing 1% BSA and aliquoted into individual tubes (between 1 ϫ 10 5 to 5 ϫ 10 5 cells per tube in 100 l volume). Monoclonal antibodies were then added to the cells, and the tubes were incubated on ice for 20 min. The cells were then washed with PBS and, when needed, cells were fixed in 1% paraformaldehyde. All monoclonal antibodies used were directly conjugated to either FITC or PE and were all obtained from BDIS.
For the analysis of flow cytometric data, a wide light scatter gate was used which included small and large cells. Such a gate was constructed to be large enough to contain some of the rosetted CD34 ϩ cells which are not released by chymopapain treatment which have a characteristic high side scatter. However, only a few of these cells were detected. Confirmation of the percentage of CD34 ϩ cells enumerated in a sample with wide open scatter gate was performed by calculating, in a dual parameter dot plot, the percentage of CD34 ϩ cells displaying low side scatter properties. In general, this percentage was within 10% of that obtained with a wide scatter gate.
Enumeration of CD3 ϩ cells in every fraction of the selection procedure was achieved by calculating the average value of CD3 ϩ events obtained from the analysis of four separate stain tubes per sample. These stains were CD3/CD4, CD3/CD8, CD3/CD16 ϩ 56, and CD3/CD19. Also in the case of CD3, the percentage obtained with wide scatter gates was confirmed for small cells in a dual dot plot displaying side scatter vs CD3.
Hematopoietic progenitor cell assays
Clonogenic assays were performed as previously outlined. 10 Briefly, 2.5 ϫ 10 4 low density marrow cells or cells from the CD34 depleted fraction or 10 3 CD34 ϩ cells were suspended in duplicate plastic 35-mm tissue culture dishes in 1 ml of 30% FBS, 5 ϫ 10 Ϫ5 mol/l 2-mercaptoethanol, 1.1% methylcellulose, 100 ng/ml SCF, 25 ng/ml IL-3, 25 ng/ml IL-6, 25 ng/ml GM-CSF, and 2 U/ml erythropoietin in IMDM. Cultures were incubated in 100% humidified 5% CO 2 in air at 37°C. After 14 days, BFU-E, CFU-GM and CFU-GEMM were enumerated using an inverted microscope. All colony types were identified according to previously reported criteria. 11 Values for the total clonogenic cell content of every fraction of cells assayed were extrapolated by multiplying the number of colonies counted by the number of cells in every fraction and dividing by the number of cells plated per ml.
Assessment of GVHD, engraftment, and relapse
The date of engraftment was defined as the first of 3 consecutive days with an absolute granulocyte count (AGC) of у500/mm 3 . Platelet engraftment was defined as the first of 3 consecutive days over 20 000 or 50 000/mm 3 beginning at least 7 days from the last platelet transfusion in accordance with the International Bone Marrow Transplantation Registry guidelines. Engraftment of donor-derived hematopoiesis and percent chimerism was confirmed by restriction fragment length polymorphism (RFLP) analysis. Acute GVHD was graded as 0-IV according to the criteria of Glucksberg et al. 12 PCR for BCR/ABL was performed as previously described. 13 
Statistical analysis
Descriptive statistics are reported as medians and ranges. Time to engraftment based on AGC and platelet engraftment curves were constructed using the KaplanMeier product limit method. 14 Cox proportional hazards regression 15 was used to evaluate the association between the number of CD34 and CD3 cells/kg infused and the time to engraftment and length of stay. Also, a Wilcoxon nonparametric test was used to test for differences between GVHD outcomes and T cell populations.
Results
Fifteen consecutive patients with matched sibling donors were registered on the study protocol. One patient was ineligible for CD34 selection due to an insufficient number of donor marrow cells obtained at the time of marrow harvest (Ͻ2 ϫ 10 8 nucleated cells/kg). The remaining 14 patients, nine men and five women, were transplanted with CD34-enriched donor marrow. The median age of participants was 42 years (range, 17-52). Patients required alloBMT for chronic myeloid leukemia in first chronic phase (four), myelodysplastic syndrome (four), acute myeloid leukemia in either first (two) or second (one) complete remission (CR), non-Hodgkin's lymphoma (two), or acute lymphoid leukemia in first CR (one).
The performance of the CD34 enrichment procedure is presented in Table 1 . At the time of harvest a mean of 3.0 Ϯ 0.2 (s.e.m.) ϫ 10 10 nucleated cells were collected. After low density centrifugation, 1.1 Ϯ 0.1 ϫ 10 10 mononuclear cells were placed on the Isolex 300 separation column. Of the cells added to the selection column, 1.74 Ϯ 0.27% were CD34 ϩ and 22.0 Ϯ 2.2% were CD3 ϩ T cells. After selection, the CD34-enriched product contained a mean of 1.27 Ϯ 0.17 ϫ 10 8 mononuclear cells and the mean dose per patient was 1.83 Ϯ 0.22 ϫ 10 6 mononuclear cells/kg. The purity, or percentage of CD34 ϩ cells in the selected product, was 64.9 Ϯ 6.0%. Patients were transplanted with a mean of 1.24 Ϯ 0.21 ϫ 10 6 CD34 ϩ cells/kg. An average of 46.3 Ϯ 6.4% of CD34 cells placed on the column were recovered by the selection device (Table 1) . While the Table 1 Analysis of marrow product before and after CD34 selection Cell infusion data and engraftment rates for all patients are presented in Table 2 . There were no cases of graft rejection. Granulocyte engraftment was rapid (Figure 1) , with patients attaining a sustained absolute granulocyte count of у500/mm 3 in a median of 10.5 days (range, 9-12). As shown in Figure 1 , the median time to sustained platelet engraftment Ͼ20 000/mm 3 was 27 days (range 18-49). Patients attained a sustained platelet count of 50 000/mm 3 in a median of 31.5 days (range 18-165 days). There was no correlation between CD34 counts and time to granulocyte engraftment, platelet engraftment of Ͼ20 000, or platelet engraftment of Ͼ50 000 (P ϭ 0.25, 0.46 and 0.50, respectively).
As depicted in Table 3 , there was a 2.7 Ϯ 0.1 log decrease in the number of T cells within the transplanted marrow. On average, patients received 9.4 Ϯ 1.7 ϫ 10 4 CD3-positive cells/kg (Table 3) . Five patients had no evidence of GVHD while grade I GVHD developed in five patients and grade II GVHD was noted in four patients (Table 3) . GVHD was limited to the skin in all but one patient, who developed skin and gut GVHD. No severe GVHD (grade III-IV) was noted. There was no correlation between CD3 counts and time to granulocyte engraftment, platelet engraftment of Ͼ20 000, or platelet engraftment of Ͼ50 000 (P ϭ 0.59, 0.21, and 0.95 respectively). There was no correlation between the number of CD3
ϩ 56 ϩ cells infused/kg and the development of GVHD when comparing patients with no GVHD vs those with grade I-II GVHD, or when comparing patients with grade 0-I and those with grade II disease.
The use of CD34-enriched cells in allogeneic transplantation has been well tolerated. One patient developed mild rigors during marrow infusion, while there were no objective or subjective toxicities noted in the remaining 13 patients. During the immediate post-transplantation period no one required dialysis or mechanical ventilation. All patients were discharged from the hospital within the median length of stay after marrow infusion being 21.5 days (range . There was no correlation between length of stay and the number of CD34 or CD3 cells inflused/kg (P ϭ 0.81 and 0.51, respectively). With a median follow-up of 11.9 months (range 6.0-16.9), the estimated 100 day survival is 86 Ϯ 9% and the estimated 1-year survival is 70 Ϯ 13% (Figure 2 ). There have been four deaths, one case each of veno-occlusive disease, encephalitis, interstitial pneumonia and Epstein-Barr virus lymphoproliferative disorder (EBV-LPD). The patient with EBV-LPD had previously been hospitalized for severe pharyngitis and is felt to have contracted a primary EBV infection in the post-transplant period. This patient had a partial but incomplete response to donor T cell infusion. In addition to rapid engraftment, trilineage hematopoiesis has been maintained ( Figure 3) . RFLP data was performed to assess the origin of engrafted cells and is available for 12 patients. Ten of 12 patients tested within 1-3 months of transplant had 100% donor cells. One patient was trace (Ͻ5%) recipient at 1 month but was 100% donor when tested at 3 and 6 months. Another patient was 5% recipient at 3 months and had a cytogenetic relapse of CML at 6 months. After infusion of donor lymphocytes the patient is 100% donor by RFLP at 10 and 12 months and cytogenetically normal. PCR for BCR/ABL RNA was positive at 3 and 6 months but was negative at 10 and 12 months (level of sensitivity one in 10 6 cells). Ten patients evaluated at 6 months by RFLP were 100% donor and two additional patients evaluated by cytogenetics alone were all donor (50 metaphases evaluated). Four patients evaluated at 1 year are 100% donor by RFLP.
Discussion
Bone marrow contains an array of hematopoietic progenitors at various stages of differentiation. The majority of transplanted marrow cells are at or near terminal differentiation, do not contribute significantly to engraftment, and do not express the CD34 antigen. 3, 16 During BMT, hematopoietic reconstitution appears to involve two populations of CD34-expressing cells. The first is responsible for initial engraftment and is composed of committed progenitors with an impressive capacity for expansion and differentiation but whose life span is finite. The rapid engraftment UPN ϭ unique patient number; GVHD ϭ graft-versus-host disease; NT ϭ not tested; ND ϭ none detected. s.e. ϭ standard error of the mean. of CD34-enriched marrow cells in autologous BMT supports the hypothesis that CD34 cells are responsible for short-term engraftment. 4, 5, 17 Long-term hematopoiesis after BMT is believed to arise from a second population of CD34 cells, stem cells, which differentiate into committed progenitors and also have the capacity for self-renewal. [18] [19] [20] The rate of granulocyte engraftment using CD34-enriched marrow (median 10.5 days) correlates favorably with allogeneic transplantation regimens using the soybean lectin agglutination and sheep red blood cell-rosette (SBA/sRBC) method of T depletion, 21 and autologous transplantation regimens which utilize cytokines post-transplantation. 6, 22 The rate of granulocyte engraftment was superior to allogeneic transplantation using post-transplantation cytokines and methotrexate. [23] [24] [25] In this study, platelet engraftment (median 27 days) was similar to that reported in allogeneic transplantation using post-transplantation GM-CSF and methotrexate. 24, 26 In contrast to others, 22 we did not identify a correlation between CD34 ϩ cell numbers and engraftment time. Additional accrual will be required to provide sufficient power to determine whether a true correlation exists. GVHD was limited to grade II or less without the prophylactic use of methotrexate or cyclosporin A. There was no correlation between the number of T cells infused and the risk of GVHD. This is in contrast to previous studies 27, 28 which report an increased risk of GVHD with increasing T cell number but similar to our findings with SBA/sRBC T cell depletion. 21 CD34 ϩ cell selection depleted the number of T cells to less than 2 ϫ 10 5 CD3 cells/kg, a dose which may be below the threshold required to abrogate significant acute GVHD in sibling transplants. Recently, Link et al 29 reported engraftment of CD34-enriched peripheral blood progenitor cells (PBPC) in patients undergoing allogeneic transplantation. Rate of granulocyte engraftment was similar to our findings, despite their patients receiving approximately seven times the number of CD34-positive cells. Unlike our study, Link et al 29 noted a high incidence of GVHD, with four of five patients developing grade III-IV GVHD if they received cyclosporin A alone as prophylaxis. Bensinger et al 30 also noted higher than expected GVHD using CD34-selected peripheral blood stem cells. Compared to patients in our study, their patients received approximately 10 times the number of T cells which may explain the high incidence of severe GVHD. Other potential explanations include differences in the CD34 selection device or differences in the graft source (marrow vs PBPC).
A concern with decreasing T cells in marrow grafts is an increased incidence of non-engraftment and graft rejection. Rates as high as 18% have been reported when marrow T cells are depleted prior to transplantation. 8, [31] [32] [33] The use of antithymocyte globulin, glucocorticoids, thiotepa, and intensification of total body irradiation have been reported to decrease the incidence of graft rejection. 8, 34 In a previous trial, we incorporated these agents with G-CSF and noted a graft rejection rate of 2.4% in 42 patients undergoing matched and mismatched sibling and unrelated transplantation utilizing marrow depleted of T cells by the SBA/sRBC method. 21 The use of this preparative regimen in this pilot study of CD34 selection was associated with engraftment in all 14 patients.
Patient mortality was related to infectious complications including EBV-LPD and is consistent with previous studies utilizing T cell depletion in allogeneic transplantation. 8, 35, 36 Increased relapse rates from CML is also anticipated and we continue to reserve CD34 selection for older CML patients with a high risk of GVHD. [37] [38] [39] Donor lymphocyte infusion was associated with a complete response in our patient who relapsed from CML. Infectious complications can also respond to lymphocyte infusion 35, 40 but the usefulness of T cell-depleted BMT followed by donor lymphocyte infusion, either as prophylaxis or as treatment, remains to be determined.
Since all of our patients engrafted, we cannot define the absolute number of CD34 cells required for allogeneic bone marrow transplantation. Previous studies in autologous BMT have aimed to use between 1 and 5 ϫ 10 6 CD34 ϩ cells/kg, 4, 5, 19 but reconstitution has been reported with patients transplanted in the range of 10 5 cells/kg. 22 Our current findings suggest that allogeneic transplantation of greater than 2 ϫ 10 5 CD34 ϩ cells/kg is associated with successful engraftment. This is consistent with our experience in 42 patients receiving the identical preparative regimen and marrow depleted of T cells by the SBA/sRBC method. 21 Patients transplanted using the SBA/sRBC method received a mean of 7.3 ϫ 10 5 CD34 cells/kg with sustained long-term engraftment attained in 97.6% of patients.
Toxicity associated with infusion of CD34-enriched marrow was limited to one case of self-limiting rigors. During the immediate post-transplantation period there were no unanticipated adverse reactions and all patients were discharged from the hospital. While the limited number of patients in this study prevents us from drawing firm conclusions from outcome data, the 100-day survival and estimated 1 year survival are favorable and indicate that further evaluation of CD34 selected marrow in allogeneic BMT is warranted.
